AN2 Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 25, 2025

ANTX$4.33+8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

BALANCE SHEETS

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$21,351	$15,647
Short-term investments	62,267	91,648
Prepaid expenses and other current assets	2,644	3,212
Total current assets	86,262	110,507
Long-term investments	5,021	27,194
Other assets, long-term	804	1,043
Total assets	$92,087	$138,744
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,317	$2,676
Accrued compensation	1,676	4,018
Accrued liabilities	4,454	6,681
Other current liabilities	791	666
Options subject to repurchase, short-term	—	2
Total liabilities	10,238	14,043
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at December 31, 2024 and December 31, 2023	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023; 29,919,634 and 29,741,445 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	—	—
Additional paid-in capital	287,594	278,881
Accumulated other comprehensive gain	31	275
Accumulated deficit	(205,776)	(154,455)
Total stockholders’ equity	81,849	124,701
Total liabilities and stockholders’ equity	$92,087	$138,744

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.